AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $521.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
AbbVie Inc (ABBV) P/E Ratio & Valuation History
AbbVie (ABBV) trades at 23.0x trailing earnings and 7.9x sales. Its P/E of 23.0x is above its 5-year median of 15.9x. Its forward P/E is 18.2x. The median P/E across 9 similar companies is 20.0x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 26.4% higher over the next year. Its free cash flow yield is 3.6%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 23.0x |
| Forward P/E | 18.2x |
| Price to sales | 7.9x |
| EV/EBITDA | 25.5x |
| Price to FCF | 27.6x |
| EV/FCF | 31.3x |
| PEG | 0.6 |
| FCF yield | 3.6% |
Historical Medians
Against its 10-year medians, its P/E is 84.0% above 12.5x and its P/S is 71.7% above 4.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 23.0x | 15.9x | 12.5x |
| P/S | 7.9x | 5.5x | 4.6x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 9.9x in 2019 to 22.8x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $228.49 | 22.8x | 6.6x | N/A |
| 2024 | $177.70 | 17.6x | 5.6x | 93.7x |
| 2023 | $154.97 | 13.9x | 5.0x | 26.4x |
| 2022 | $161.61 | 11.7x | 4.9x | 16.6x |
| 2021 | $135.40 | 10.7x | 4.3x | 15.6x |
| 2020 | $107.15 | 10.2x | 3.9x | 14.6x |
| 2019 | $88.54 | 9.9x | 3.9x | N/A |
| 2018 | $92.19 | 11.7x | 4.3x | N/A |
| 2017 | $96.71 | 17.3x | 5.5x | 30.4x |
| 2016 | $62.62 | 13.0x | 4.0x | 21.9x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ABBV
What is ABBV's forward P/E ratio?
AbbVie has a forward P/E ratio of 18.2x.
Is ABBV stock overvalued?
GNG's valuation label for ABBV is Overvalued. Its P/E of 23.0x compares with a median of 20.0x across 9 similar companies.
What is ABBV's price to sales ratio?
AbbVie has a price to sales ratio of 7.9x.
What is AbbVie's average P/E ratio over 5 years?
AbbVie's median P/E over the last 5 years is 15.9x, from 60 month-end values through Oct 2026.
What is ABBV's PEG ratio?
AbbVie has a PEG ratio of 0.6.
ABBV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts